There were similar conclusions in young patients (20–31) and in patients with infiltrating lobular histologies (32–34) and HER2/neu positive cancers (15–17, 25, 35) which show higher recurrence rates than in older patients with non- lobular or HER2/neu positive tumors. This evidence concerns the gene ERBB2 and cancer.